Carregant...
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival. Constitutive activation of the janus kinase/signal transducer and activator of transcription (...
Guardat en:
| Publicat a: | Leukemia |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Nature Publishing Group UK
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7787977/ https://ncbi.nlm.nih.gov/pubmed/32647323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-020-0954-2 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|